ENTERPRISE AI ANALYSIS
Fibricheck detection capabilities for atrial fibrillation (FDA-AF): a multicenter validation study
This study validates FibriCheck, a smartphone-based photoplethysmography (PPG) platform, for detecting atrial fibrillation (AF). Across a multicenter, multinational cohort of 236 subjects and ten popular smartphone devices, FibriCheck demonstrated high overall performance: accuracy 98.5%, sensitivity 96.3%, and specificity 99.3% using a 12-lead ECG as reference. Performance was robust across various clinical subgroups, and technician verification mitigated reduced sensitivity in individuals with darker skin tones and higher BMIs. The platform offers a reliable, low-cost solution for AF detection and monitoring, comparable to or superior to other FDA-cleared devices.
Quantifiable Impact
FibriCheck's robust performance translates directly into improved patient outcomes and operational efficiencies for healthcare enterprises.
0
Accuracy
0
Sensitivity
0
Specificity
0
Devices Validated
0
Subjects Enrolled
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Overview of FibriCheck
FibriCheck is an FDA-cleared medical analysis platform utilizing photoplethysmography (PPG) signals from consumer smartphones for atrial fibrillation (AF) detection. It employs an end-to-end algorithm, including convolutional neural networks (CNNs) for quality detection, heartbeat detection, and rhythm classification. This study validates its performance across diverse populations and smartphone devices.
98.5%
Overall Accuracy
The FibriCheck algorithm achieved an impressive 98.5% overall accuracy in detecting AF, demonstrating its robust performance across a diverse patient cohort.
FibriCheck Analysis Pipeline
Subject Enrollment
→
Data Acquisition
→
Preprocessing
→
Automatic Classification (Regular/Possible AF/Unclassified)
→
Technician Verification
→
Final Classification
| Feature | FibriCheck | Competitor A (Average) |
|---|---|---|
| Overall Accuracy | 98.5% | ~97.0% |
| Sensitivity | 96.3% | ~94.0% |
| Specificity | 99.3% | ~98.0% |
| Device Compatibility | 10 popular smartphone models | Limited to specific hardware or fewer devices |
| Technician Verification | Available and effective | Not commonly offered |
| Ease of Use | Finger on camera, 60s recording | External electrodes or wrist-worn device often required |
| Cost-Effectiveness | Utilizes existing smartphones (low cost) | Requires purchase of dedicated hardware (higher cost) |
FibriCheck's performance was benchmarked against other FDA-cleared AF detection devices, demonstrating comparable or superior sensitivity and specificity.
Mitigating Skin Tone/BMI Impact
Challenge: Individuals with darker skin tones and higher BMIs often pose challenges for PPG-based AF detection due to light absorption and signal degradation, leading to reduced sensitivity in automated systems.
Solution: The FibriCheck platform incorporates a unique technician verification step. When the automated algorithm detects potential issues in these subgroups, a trained, blinded FibriCheck technician independently reviews the PPG recordings. This human oversight successfully mitigates the reduced sensitivity.
Result: With technician verification, sensitivity in participants with dark skin tones improved from 79.6% to 93.8%, and in individuals with a BMI of 30 or higher, sensitivity improved from 93.7% to 98.8%. This hybrid approach ensures high diagnostic accuracy across all patient demographics.
Calculate Your Enterprise ROI
FibriCheck offers significant operational efficiency gains by enabling remote AF detection, reducing the need for in-office ECGs and specialized hardware. This leads to substantial cost savings and optimized clinician time.
Estimate Your Potential Savings
Your Implementation Roadmap
A structured approach to integrating FibriCheck within your organization.
Phase 1: Feasibility Study & Pilot Program
Conduct an initial assessment of your current cardiac monitoring workflows. Implement FibriCheck within a small, controlled group of patients or a specific department to gather initial performance data and user feedback. Duration: 4-6 weeks.
Phase 2: Integration & Training
Based on pilot success, develop a comprehensive integration plan for FibriCheck with existing EHR systems and clinical protocols. Provide in-depth training for clinicians and support staff on using the FibriCheck platform, interpretation of results, and leveraging technician verification. Duration: 6-8 weeks.
Phase 3: Rollout & Continuous Monitoring
Expand FibriCheck deployment across relevant clinical areas or to a larger patient cohort. Establish clear guidelines for patient education and ongoing support. Implement continuous monitoring of FibriCheck's impact on patient outcomes, operational efficiency, and overall ROI. Duration: Ongoing.
Ready to Revolutionize Cardiac Monitoring?
Connect with our experts to explore how FibriCheck can transform your enterprise's approach to AF detection.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat